{"id":14005,"date":"2024-02-12T17:34:49","date_gmt":"2024-02-12T16:34:49","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=14005"},"modified":"2024-03-01T10:37:24","modified_gmt":"2024-03-01T09:37:24","slug":"special-new-aifa-cse-and-reorganisation","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/special-new-aifa-cse-and-reorganisation\/","title":{"rendered":"New AIFA Special Update: CSE and REORGANISATION"},"content":{"rendered":"

Update 1 March 2024<\/em><\/h2>\n

Below is the updated document with appointments and update timeline to 1 March 2024.<\/p>\n

Original text<\/em><\/h3>\n

Pharma Value<\/strong>\u00a0developed with\u00a0Nomos<\/a>\u00a0a\u00a0background document with the update<\/strong> of the appointments of members<\/strong> that will make up the new CSE (Scientific and Economic Commission)<\/strong>, of the administrative and technical-scientific directors<\/strong>of the President<\/strong> reconfirmed and the 2 members of the CDA<\/strong> of its competence, on the basis of the amendments requested by the State-Regions Conference and the Council of State.<\/p>\n

We also carried out a focus on the characteristics of the members with regard to gender, profession, region of origin.<\/p>\n

L'target<\/strong>\u00a0is to offer one\u00a0useful tool for orientation in AIFA's reorganisation activities<\/strong>.<\/p>\n

Reflection is needed on the Agency's mission and the relative suitability of the new apparatus to govern Italian pharmaceutical expenditure.<\/p>\n

The latest data from AIFA's Osmed Report indicate total national expenditure (public and private) of EUR 34.1 billion in 2022, an increase of 6.0% compared to 2021. A growth trend that is also being confirmed for 2023. The value of total pharmaceutical expenditure added to out-of-pocket expenditure (about 40 billion) represents more than 4% of the national GDP.<\/p>\n

The hope is that the new AIFA will be adequate to manage these numbers and to enhance a sector that is often governed only as a source of revenue or expenditure and not as a resource in which to invest for the country's economic growth.<\/p>\n

Nomos and Pharma Value undertake to update the document with legal-institutional news, information and reflections on the basis of forthcoming developments relating in particular to the approval of the New AIFA Regulation by the CDA.<\/p>\n

If you want to learn more about the AIFA Governance Reform in its various approval steps, read our article: Special Commission Update No. 3 - Towards the reform of the governance of the Italian Medicines Agency and the Single Commission: where are we?<\/a><\/p>\n

<\/div>